Back to News
Market Impact: 0.35
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Source: GlobeNewswire
Healthcare & BiotechTechnology & InnovationCompany Fundamentals
GSK selected a development candidate using Wave Life Sciences' SpiNA design siRNA platform, triggering a milestone payment to Wave. Three additional programs under the companies' collaboration are also advancing, supporting validation of Wave's RNA-editing technology and potential future milestone economics.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
GSK0.34
WVE0.78
More News
- South Korea’s exports hit record high on AI boom
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- PHC Holdings surge to near 4-year high after Toho takeover proposal confirmed
- Asia stocks rise on chipmaker gains, soft U.S. inflation; Nikkei outperforms
- Why is Nidec stock plunging today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI
- How to Track Earnings Call Sentiment Across Companies